Seattle Genetics, Inc. 보도자료 - 뉴스와이어

기업 뉴스룸

Seattle Genetics, Inc.

바이오테크

BOTHELL, Wash.

Seattle Genetics, Inc. 보도자료

5개

RSS 이메일

2017년 10월 6일 15:25

Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced final data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymph

건강 바이오테크 개발

2017년 6월 8일 18:55

Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the randomized Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lympho

건강 바이오테크 개발

2016년 11월 9일 11:20

Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma

Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced completion of patient enrollment in the ECHELON-2 clinical trial. ECHELON-2 is a global phase 3 randomized trial evaluating ADCETRIS (brentuxim

건강 바이오테크 개발

2014년 9월 30일 15:15

Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma

Seattle Genetics, Inc. (www.seattlegenetics.com) (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that patients with Hodgkin lymphoma (HL) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immedia

건강 바이오테크 개발

2014년 9월 30일 15:15

시애틀 제네틱스와 다케다, 애드세트리스(ADCETRIS®) 임상 3상 시험 AETHERA에서 긍정적 결과 도출…이식 후 호지킨 림프종 환자의 공고요법 시험

시애틀 제네틱스(Seattle Genetics, Inc., www.seattlegenetics.com)(나스닥: SGEN)와 다케다 파마슈티컬 컴퍼니 리미티드(Takeda Pharmaceutical Company Limited)(도쿄증권거래소: 4502)는 호지킨 림프종(HL) 환자 중 자가조혈모세포 이식(ASCT) 후 곧바로 애드세트리스(ADCETRIS)(성분명: 브렌툭시맙 베도틴)를 공고 요법으로 투여한

건강 바이오테크 개발